Biotech entity
Every one of those 3 sits in a single category, pharma. Adam Alanoff is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 168-day window averages about 0.1 stories each week. Source depth averages 3 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: Aug 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 3 sits in a single category, pharma. Adam Alanoff is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 168-day window averages about 0.1 stories each week. Source depth averages 3 original sources per story, versus 3.6 across the same-window beat baseline. Their average consequence score of 6 runs below the beat's 6.2 for that window. This profile follows 3 Biotech stories mentioning GLP-1 across the period from February 24, 2026 to August 10, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 653 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1. Shared-story counts are live from our verified record — not editorial picks.
Patent Extension
Secured Rezdiffra patent protection through 2045.
DGAT-2 and siRNA Expansion
Acquired late-stage DGAT-2 inhibitor and six preclinical siRNA assets.
GLP-1 Acquisition
Madrigal paid $120 million upfront to acquire an oral GLP-1 program.
Rezdiffra Commercial Launch
First full year of Rezdiffra availability in the U.S. market for MASH.
Novo Nordisk’s Q2 earnings reveal explosive uptake of its oral Wegovy pill, now commanding 90% of the U.S. oral obesity market with 267,000 weekly scripts. The therapy is expanding the GLP-1 market, with 80% of users being treatment-naïve, signaling a new era in obesity pharmacotherapy.
Source: tickerreport.com · finance.yahoo.com
Agilent reported a 4.4% core revenue growth in Q1 2026, driven by a strong 7% uptick in the pharmaceutical sector despite an 8% decline in academic and government markets. The company is navigating margin pressures from new tariffs while leaning into high-growth areas like GLP-1 manufacturing and CDMO services.
Madrigal Pharmaceuticals reported a transformative 2025, with Rezdiffra net sales reaching $958.4 million during its first full year on the market. The company is aggressively pivoting toward a multi-asset metabolic powerhouse, integrating oral GLP-1 and DGAT-2 programs alongside its core MASH franchise.
GLP-1 is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
